PSMA掃描為標的進展性前列腺癌的治療策略

陳思如、裘坤元

台中榮民總醫院泌尿部

Treatment strategy after PSMA for advanced Prostate Cancer

Szu-ju Chen, Kun-yuan Chiu

Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan

 

Purpose: Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein on the surface of prostate cells and is highly expressed in poorly dfferentiated, metastatic, and castration-resistant prostate cancer. PSMA has gained increasing interesting as target molecule on image diagnosis and treatment for advanced prostate cancer due to labelled antibody can bind its extracellular domain. Therefore, it can be early localization of metastatic cancer cells than conventional image technique.

Materials and Methods: We enrolled 9 patients with prostate cancer which pathological staging above T2. All patients underwent radical prostatectomy (age ranged from 60 to 78, mean 69-year-old) and presented cancer progression after hormone therapy.

Results: They were further diagnosed by 68Ga-PSMA–PET imaging in combination with multiparametric MRI (mpMRI) for cancer localization after castration (mCRPC). All patients under PSMA-based radioligand therapy. The result will be presented.

Conclusions: In conclusion, the application of PSMA is becoming mature for the diagnosis and treatment of mCRPC based on our preliminary result.

    位置
    資料夾名稱
    摘要
    發表人
    TUA秘書處
    單位
    台灣泌尿科醫學會
    建立
    2020-12-25 14:26:32
    最近修訂
    2020-12-25 14:30:50
    瀏覽
    123
    1. 1.
      Podium 01
    2. 2.
      Podium 02
    3. 3.
      Podium 03
    4. 4.
      Moderated Poster 01
    5. 5.
      Moderated Poster 02
    6. 6.
      Moderated Poster 03
    7. 7.
      Non-Discussion Poster